Abstract:
Disclosed are macrocyclic compounds of formulae I, I', II, II', III, III', IV, and V, which are analogs of the pochonin resorcylic acid lactones, pharmaceutical compositions comprising the compounds, and methods and uses comprising the compounds for the treatment of diseases mediated by kinases and Heat Shock Protein 90 HSP90.
Abstract:
"composto da fórmula i ou i', composição farmacêutica, método de tratamento de um paciente com uma doença, uso do composto", trata-se a presente invenção de compostos macrociclos das fórmulas i, 1', 11, 11', 111, 111', iv e v', que são análogos das lactonas do ácido resorcílico, como, por exemplo, porchonina, e composições farmacêuticas compreendendo os compostos para o tratamento de doenças mediadas por quinase e proteína de choque térmico 90 (hsp90).
Abstract:
Disclosed are macrocyclic compounds of formulae l-V, which are analogs of the pochonin resorcylic acid lactones, and processes for the preparation of the compounds. The compounds disclosed are useful as inhibitors of kinases and Heat Shock Protein 90 (HSP 90). Also disclosed are pharmaceutical compositions comprising an effective kinase-inhibiting amount or an effective HSP90-inhibiting amount of the compounds and methods for the treatment of disorders that are mediated by kinases and HSP90. (see formula I)
Abstract:
Disclosed are macrocyclic compounds of formulae I-V,which are analogs of the pochonin resorcylic acid lactones, and processes for the preparation of the compounds. The compounds disclosed are useful as inhibitors of kinases and Heat Shock Protein 90 (HSP 90). Also disclosed are pharmaceutical compositions comprising an effective kinase-inhibiting amount or an effective HSP90-inhibiting amount of the compounds and methods for the treatment of disorders that are mediated by kinases and HSP90.
Abstract:
Un compuesto de fórmula II o II', o un tautómero del mismo, una sal, solvato o éster farmacéuticamente aceptable del mismo:**Fórmula** en la que: X es O, S o NR; Y es -OR, -O-(CH2)mCOOR, -O-(CH2)mCON(R)2, -N(R)2, -N(R)SOR o -N(R)SO2R, en el que los grupos unidos al átomo de nitrógeno pueden estar en una configuración Z o E; R1 y R2 son independientemente hidrógeno o halógeno; R3, R4, R5, R6, R7, R8, R9 y R10 son independientemente hidrógeno, halógeno, azido, nitro, ciano, alifático, alquilarilo, aralquilo, arilo, heteroalquilo, alquilheteroarilo, heterociclilo, heteroarilo, OR, N(R)2, SR, -O(CH2)mN(R)C(O)(CH2)pR, -O(CH2)mOC(O)(CH2)pR, -O(CH2)mC(O)(CH2)pN(R)2, -O(CH2)mC(O)(CH2)pOR, -O(CH2)mN(R)C(O)(CH2)pOR, -O(CH2)mN(R)C(O)(CH2)pN(R)2, -O(CH2)mOC(O)(CH2)pOR, -O(CH2)mOC(O)(CH2)pN(R)2, -NR(CH2)mN(R)C(O)(CH2)pR, -NR(CH2)mOC(O)(CH2)pR, -NR(CH2)mC(O)(CH2)pN(R)2, -NR(CH2)mC(O)(CH2)pOR, -NR(CH2)mN(R)C(O)(CH2)pOR, -NR(CH2)mN(R)C(O)(CH2)pN(R)2, -NR(CH2)mOC(O)(CH2)pOR, -NR(CH2)mOC(O)(CH2)pN(R)2, -(CH2)mN(R)C(O)(CH2)pR, -(CH2)mOC(O)(CH2)pR, -(CH2)mC(O)(CH2)pN(R)2, -(CH2)mC(O)(CH2)pOR, -(CH2)mN(R)C(O)(CH2)pOR, -(CH2)mN(R)C(O)(CH2)pN(R)2, -(CH2)mOC(O)(CH2)pOR, -(CH2)mOC(O)(CH2)pN(R)2, -(CH2)mN3, -O(CH2)mN3-(CH2)mN(R)2, -(CH2)mOR, -(CH2)mS(O)(CH2)pR, -(CH2)mS(O)2(CH2)pR, -(CH2)mSO2(CH2)pN(R)2 o -(CH2)mN(R)SO2(CH2)pR; y cada R es independientemente R11, hidrógeno, alifático, amino, azido, ciano, nitro, alquilamino, dialquilamino, OH, alcoxi, carbonilamino, aminocarbonilo, alcoxicarbonilo, carboniloxi, carboxi, acilo, arilo, alcarilo, arilalquilo que incluye bencilo, heteroalquilo, heteroarilo, heterociclilo, o un grupo protector seleccionado entre un grupo que consiste en etoximetilo, metoximetilo, terc-butildimetil sililo (TBS), fenildimetilsililo, trimetilsililo (TMS), 2-trimetilsililetoximetilo (SEM), 2-trimetilsililetilo; y bencilo; o dos R en el mismo nitrógeno se toman junto con el nitrógeno para formar un anillo heterocíclico o heteroarilo de 5-8 miembros; en el que un grupo contiene más de un sustituyente R; en el que R está opcionalmente sustituido, y cada R puede ser igual o diferente; R11 es el grupo: donde Z es un contraión inorgánico u orgánico; m y p son independientemente 0, 1, 2, 3, 4 o 5; y en el que, en la fórmula II', cuando X es O, entonces al menos uno de R5, R6, R7, R8, R9 o R10 no es hidrógeno.
Abstract:
Disclosed are macrocyclic compounds of formulae I, I', II, II', III, III', IV, and V, which are analogs of the pochonin resorcylic acid lactones, pharmaceutical compositions comprising the compounds, and methods and uses comprising the compounds for the treatment of diseases mediated by kinases and Heat Shock Protein 90 HSP90.
Abstract:
Disclosed are macrocyclic compounds of formulae I-V,which are analogs of the pochonin resorcylic acid lactones, and processes for the preparation of the compounds. The compounds disclosed are useful as inhibitors of kinases and Heat Shock Protein 90 (HSP 90). Also disclosed are pharmaceutical compositions comprising an effective kinase-inhibiting amount or an effective HSP90-inhibiting amount of the compounds and methods for the treatment of disorders that are mediated by kinases and HSP90.